Loading page…

Auro Laboratories Ltd (AUROLAB) · mywealthgrid

About

Auro Laboratories is a small-scale pharmaceutical company with standalone quarterly revenues of ₹9–10 Cr and market cap ₹146.48 Cr. Operating margins have expanded to 43.28% (Dec 2025) from a historical average of 19.91%, but remain volatile. The company operates in the domestic generic pharma sector and has declined 27% in revenue since 2021.

Face value: ₹10

Market cap

₹151 Cr

P/E

19.4×

P/B

3.6×

Dividend yield

ROE

20.5%

ROCE

22.3%

Debt / equity

0.63

OPM

19.9%

EPS (TTM)

₹12.5

Book value

₹67.4

52-week high

₹302.1

52-week low

Key insights

Company research notes and source-linked reviews

Key risks

Revenue declined 27% from ₹13.57 Cr (Mar 2021) to ₹9–10 Cr (recent quarters). What caused this loss, and has the decline arrested?
Operating margin volatility ranges from 1.18% (Jun 2025) to 43.28% (Dec 2025), indicating product/customer concentration or high operational leverage. Which scenario represents structural profitability?
Loss-making quarter: Jun 2025 recorded negative net profit (₹–0.11 Cr), revealing vulnerability to revenue swings. Can debt servicing withstand sustained downturns given D/E 0.63?
Institutional skepticism: FII holding is 0% despite PE 18.8 and ROE 20.46%. What concerns prevent institutional capital participation?

Generated analysis · source review pending

Growth drivers

Operating margin expansion: OPM 43.28% (Dec 2025) vs 19.91% average—if sustained, profits scale on flat revenue
ROE 20.46% compounds if reinvested; verify dividend payout ratio and capex allocation strategy
D/E 0.63 enables redeployment to higher-margin products or capacity expansion without leverage strain
Domestic pharma sector tailwinds (government manufacturing support, healthcare demand growth)—verify whether Auro's product portfolio benefits from these opportunities

Generated analysis · source review pending

₹243.8+5.7%1Y

Beta

0.88

Moves with the index

Volatility (1y)

47.4%

Annualised, daily returns

RSI (14)

38.1

Neither overbought nor oversold

Rel. strength (1y)

-8.7%

Behind the market

Beta is measured against NIFTY 50 over three years of weekly returns — 1 moves with the index, above 1 amplifies it, below 1 damps it.

Quick read

rule-based

Pros

+Comfortable interest coverage of 15×

Cons

−Revenue shrank over the last 3 years (-0.4% a year)

Research score

Structured signal from quality, growth, valuation and momentum.

42/100

Business quality: 68
Growth: 5
Valuation: 65
Momentum: 32

Revenue & net profit

₹ crore, by fiscal year

RevenuePAT

Margins

% of revenue, by fiscal year

OPMPAT margin

Peers

Comparable companies from the narrowest available industry classification.

Screen this industry Compare top 5 side-by-side

Company	Mkt Cap	EV	Revenue	EBITDA	OPM	PAT	NPM	ROCE	ROE	WC Days
Torrent Pharmaceuticals LimitedTORNTPHARMTORNTPHARM	₹1,61,325 Cr	₹1,76,123 Cr	₹15,723 Cr	₹5,191 Cr	32.6%	₹2,181 Cr	15.3%	14.5%	27.1%	163
Zydus Lifesciences LimitedZYDUSLIFEZYDUSLIFE	₹1,14,284 Cr	₹1,26,053 Cr	₹28,592 Cr	₹8,316 Cr	31.2%	₹4,513 Cr	18.9%	23.4%	19.7%	212
Laurus Labs LimitedLAURUSLABSLAURUSLABS	₹1,07,176 Cr	₹1,09,573 Cr	₹7,270 Cr	₹2,034 Cr	26.1%	₹1,093 Cr	13.1%	21.3%	18.2%	263
Mankind Pharma LimitedMANKINDMANKIND	₹1,04,696 Cr	₹1,11,007 Cr	₹14,738 Cr	₹3,827 Cr	25.3%	₹2,068 Cr	13.6%	14.2%	12.5%	117
Aurobindo Pharma LimitedAUROPHARMAAUROPHARMA	₹97,389 Cr	₹1,05,065 Cr	₹34,935 Cr	₹7,085 Cr	20.3%	₹3,713 Cr	10.4%	14.7%	9.9%	252
Lupin LimitedLUPINLUPIN	₹92,866 Cr	₹98,777 Cr	₹29,967 Cr	₹9,538 Cr	31.5%	₹5,529 Cr	19.2%	34.2%	26.9%	181
Glenmark Pharmaceuticals LimitedGLENMARKGLENMARK	₹65,781 Cr	₹65,781 Cr	₹17,737 Cr	₹4,797 Cr	26.9%	₹1,496 Cr	8%	37.8%	0%	83
Alkem Laboratories LimitedALKEMALKEM	₹62,431 Cr	₹64,055 Cr	₹15,081 Cr	₹3,032 Cr	20.4%	₹2,158 Cr	16%	21.5%	17.8%	152
Biocon LimitedBIOCONBIOCON	₹60,413 Cr	₹75,238 Cr	₹17,321 Cr	₹3,536 Cr	20.4%	₹495 Cr	2.2%	3.9%	1.4%	85
Abbott India LimitedABBOTINDIAABBOTINDIA	₹56,901 Cr	—	₹4,310 Cr	₹921 Cr	27.3%	₹691 Cr	22.4%	44.1%	34.5%	110
Ipca Laboratories LimitedIPCALABIPCALAB	₹49,299 Cr	₹50,003 Cr	₹10,126 Cr	₹2,232 Cr	20.5%	₹1,310 Cr	12.3%	17.8%	15.2%	308
Gland Pharma LimitedGLANDGLAND	₹47,428 Cr	₹47,671 Cr	₹6,725 Cr	₹1,751 Cr	25.3%	₹1,129 Cr	16%	14.8%	10.5%	255

Loading peers…

Financials

Reported profit and loss, balance sheet, cash flow and growth history.

Annual Quarterly

Consolidated Standalone

Consolidated figures · ₹ crore

₹ Cr	Mar 2021	Mar 2022	Mar 2023	Mar 2024
	54	51	53	54
Operating expenses	—	—	—	—
Operating profit (EBITDA)	11	5	4	11
OPM %	20.7%	9.1%	8.3%	19.9%
Depreciation	1	1	1	1
Interest	0	1	1	1
	1	1	1	2
Profit before tax	11	4	3	10
Tax	—	—	—	—
	7	3	2	8
PAT margin %	13.2%	5.6%	4.6%	14.5%
EPS (₹)	—	—	—	—
EPS adjusted (₹)	11.5	4.6	3.9	12.5
Annual report	Annual report for Mar 2021	Annual report for Mar 2022	Annual report for Mar 2023	Annual report for Mar 2024

₹ Cr	Mar 2021	Mar 2022	Mar 2023	Mar 2024
Equity capital	6	6	6	6
Reserves	22	25	28	36
Borrowings	2	13	6	26
Other liabilities	11	10	16	18
Total equity & liabilities	42	55	56	86
Fixed assets	14	14	13	22
CWIP	—	—	—	—
Investments	—	—	—	—
Other assets	—	—	—	—
Total assets	42	55	56	86

₹ Cr	Mar 2021	Mar 2022	Mar 2023	Mar 2024
Cash from operations	13	-7	3	19
Cash from investing	-4	-5	-5	-39
Cash from financing	-0	10	-8	19
Net cash flow	9	-2	-10	-1
Free cash flow	—	—	—	—
CFO / Operating profit %	114%	-142.3%	74.9%	176.1%

Compounded sales growth

7 years: —
5 years: —
3 years: -0%
1 year: 1%

Compounded profit growth

7 years: —
5 years: —
3 years: 3%
1 year: 219%

Stock price CAGR

10 years: —
5 years: 16%
3 years: 29%
1 year: 0%

Return on equity

7 years

Loading financials…

Ratios

Annual operating, return, leverage and working-capital ratios.

Consolidated Standalone

Consolidated figures

Ratio	Mar 2021	Mar 2022	Mar 2023	Mar 2024
Margins
Gross margin %	—	—	—	—
EBITDA margin %	20.7%	9.1%	8.3%	19.9%
EBIT margin %	18.8%	7.1%	6.3%	17.9%
PAT margin %	13.2%	5.6%	4.6%	14.5%
Working capital
Receivable days	—	—	—	—
Inventory days	—	—	—	—
Payable days	—	—	—	—
NWC days	—	—	—	—
Leverage
Current ratio	3.05	1.87	1.97	1.29
Debt to EBITDA	0.18	2.8	1.41	2.46
Debt to equity	0.07	0.41	0.18	0.63
Interest coverage	23.8	5.7	5.3	15
Asset turnover	1.3	0.93	0.94	0.63
Return ratios
Return on assets %	17.1%	5.2%	4.4%	9.1%
Return on capital employed %	33.6%	13.9%	11.7%	22.3%
Return on equity %	25.1%	9%	7.1%	18.6%

Derived from reported annual statements. ROCE uses EBIT over capital employed (total assets less current liabilities). Day counts average the opening and closing balance; receivables turn on revenue, inventory and payables on cost of goods sold.

Loading ratios…

Shareholding

Quarterly ownership, named holders, insider transactions and disclosed deals.

Quarterly Annual

Every quarter filed · % of equity

Holder (%)	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026	Jun 2026
	41.03%	52.09%	52.15%	52.15%	52.15%	52.15%	52.18%	52.18%	52.18%	52.18%	52.18%	52.4%
FII	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%
	0.01%	0.01%	0.01%	0.01%	0.01%	0.01%	0.01%	0.01%	0.01%	0.01%	0.01%	0.01%
Government	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%
	58.96%	47.9%	47.84%	47.84%	47.84%	47.84%	47.81%	47.81%	47.81%	47.81%	47.81%	47.59%
No. of shareholders	—	—	—	—	—	—	—	—	8,860	8,640	8,405	8,315

Promoter holding up 11.37 percentage points since Sep 2023.

4 deals · 10 Jan 2022 – 31 Aug 2023

Date	Client	Type	Venue	Side	Quantity	Price	Value
31 Aug 2023	PADRONE MARKETING PVT LTD	Bulk	BSE	Buy	50,000	₹134.87	₹0.67 Cr
30 Jun 2023	AMIT DHANYAKUMAR CHORDIA	Bulk	BSE	Sell	31,240	₹80.78	₹0.25 Cr
18 May 2023	AMIT DHANYAKUMAR CHORDIA	Bulk	BSE	Buy	50,000	₹97.64	₹0.49 Cr
10 Jan 2022	VIVEK MEHROTRA	Bulk	BSE	Sell	41,944	₹140.97	₹0.59 Cr

1–4 of 4

1 / 1

Bulk deals are a client trading over 0.5% of the equity in a session, aggregated across their trades; block deals are single negotiated trades in the exchange’s block window. Each is reported by the exchange it was crossed on, so NSE and BSE rows are separate trades rather than the same trade twice.

Mr. SHARAT DEORAHExecutive Director-Chairperson related to Promoter-MD
Mr. SIDDHARTHA DEORAHExecutive Director
Mr. KIRAN SURESH KULKARNIExecutive Director
Mr. MAHENDRA KUMAR DAGANon-Executive - Independent Director
Mrs. KAVITA VIJAYAKANT SHARMANon-Executive - Independent Director
Mr. VISHAL KAILASHCHANDRA JHUNJHUNWALANon-Executive - Independent Director
Mr. Nitesh BohraChief Financial Officer
Ms. Padma TapariyaCompany Secretary & Compliance Officer

Current officeholders as filed with BSE. A person holding two offices is listed once per office.

Loading shareholding…

F&O

Current futures and options contracts with compact option-chain pages.

Not in the F&O segment

Only about 210 stocks have listed futures and options. Contracts appear here for those, refreshed after each close.

Loading f&o…

Fund holders

Mutual-fund schemes that disclosed a holding in the company.

No fund holdings on record

No scheme among the 32 fund houses on record reported a position in Auro Laboratories Ltd. Portfolios are published monthly by each AMC; coverage is still partial.

Loading fund holders…

Documents

Annual reports, exchange filings, offer documents, ratings and earnings-call material.

Announcements

Annual reports

Credit ratings

Auro Laboratories Limited has submitted the Disclosure in relation to Credit Rating obtained by the Company from Acuite Ratings & Research Limited.14 Apr 2026 from Acuite

Documents link to external sources (exchange filings, company investor pages).

Loading documents…

Events

Upcoming dates and the company’s corporate-action history.

1

Board meeting to consider results14 Aug 2026

Loading events…

Announcements

Latest exchange announcements, filings and downloadable documents.

1 month 3 months 6 months 1 year All

12 announcementsExport CSV

17 Aug 2026, 6:44 pmCompany Update

Announcement under Regulation 30 (LODR)-Newspaper Publication

Newspaper Publication PDF

Loading announcements…

Date	Category	Subject	Filing
17 Aug 2026, 6:44 pm	Company Update Newspaper Publication	Announcement under Regulation 30 (LODR)-Newspaper Publication	PDF
14 Aug 2026, 7:12 pm	Result Financial Results	Auro Laboratories Ltd - 530233 - Un-Audited Financial Results For The Quarter Ended June 30, 2026.	PDF
14 Aug 2026, 7:03 pm	Board Meeting Outcome of Board Meeting	Board Meeting Outcome for Outcome Of Board Meeting Held On August 14, 2026.	PDF
13 Aug 2026, 7:03 pm	AGM/EGM AGM	Shareholder Meeting / Postal Ballot-Scrutinizer''s Report	PDF
11 Aug 2026, 7:27 pm	AGM/EGM AGM	Shareholder Meeting / Postal Ballot-Outcome of AGM	PDF
10 Aug 2026, 7:03 pm	Board Meeting	Board Meeting Intimation for Unaudited Financial Results For The Quarter Ended June 30, 2026.	PDF
20 Jul 2026, 6:27 pm	Company Update Newspaper Publication	Announcement under Regulation 30 (LODR)-Newspaper Publication	PDF
16 Jul 2026, 6:45 pm	Company Update General	Auro Laboratories Ltd - 530233 - Regulation 36(1)(B) Of SEBI (LODR) Regulations, 2015	PDF

Auro Laboratories Ltd

Auro Laboratories Ltd

About

Key insights

Key risks

Growth drivers

Risk & technicals

Quick read

Pros

Cons

Research score

Revenue & net profit

Margins

Peers

Financials

Profit & loss

Balance sheet

Cash flow

Compounded returns

Compounded sales growth

Compounded profit growth

Stock price CAGR

Return on equity

Ratios

Ratio timeline

Shareholding

Quarterly record

Bulk & block deals

Board and management

F&O

Not in the F&O segment

Fund holders

No fund holdings on record

Documents

Announcements

Annual reports

Credit ratings

Events

Board meetings1

Announcements

Board meetings1

Ratio timeline

Quarterly record

Bulk & block deals

Board and management

Not in the F&O segment

No fund holdings on record

Announcements

Annual reports

Credit ratings

Profit & loss

Balance sheet

Cash flow

Compounded returns

Compounded sales growth

Compounded profit growth

Stock price CAGR

Return on equity

1

1